Cargando…
The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment
Sodium taurocholate cotransporting polypeptide (NTCP) acts as a cellular receptor for the hepatitis B virus infection of host hepatocytes. Previously, many studies confirmed that the NTCP p.Ser267Phe variant was a protective factor against HBV-related disease progression. We therefore designed this...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943921/ https://www.ncbi.nlm.nih.gov/pubmed/33716744 http://dx.doi.org/10.3389/fphar.2021.616858 |
_version_ | 1783662597111808000 |
---|---|
author | Wu, Lina Xu, Wenxiong Li, Xuejun Liu, Ying Wang, Lu Zhu, Shu Yang, Fangji Xie, Chan Peng, Liang |
author_facet | Wu, Lina Xu, Wenxiong Li, Xuejun Liu, Ying Wang, Lu Zhu, Shu Yang, Fangji Xie, Chan Peng, Liang |
author_sort | Wu, Lina |
collection | PubMed |
description | Sodium taurocholate cotransporting polypeptide (NTCP) acts as a cellular receptor for the hepatitis B virus infection of host hepatocytes. Previously, many studies confirmed that the NTCP p.Ser267Phe variant was a protective factor against HBV-related disease progression. We therefore designed this study to investigate whether the NTCP p.Ser267Phe variant exerts an additive anti-HBV effect in chronic hepatitis B (CHB) patients on mainstream NAs treatment. After propensity score matching (PSM), a total of 136 CHB patients were included, among whom 68 were heterozygous carriers and 68 were wild-type controls. Proportions of primary nonresponse, partial virological response, virological breakthrough and hepatitis B reactivation and the HBV DNA clearance rate at each time point were compared using the chi-square test. Kaplan-Meier analysis and matched t-tests were also performed to estimate the speed of viral clearance and serum HBV DNA reduction, respectively. The proportion of primary nonresponse was significantly lower in heterozygous carriers than in wild-type controls (p < 0.001), especially in patients using entecavir (p = 0.013). Specifically, heterozygous carriers achieved HBV DNA clearance faster than wild-type controls (log-rank p = 0.0198). HBV DNA levels were reduced more in heterozygous carriers after 12 weeks (p < 0.001) and 24 weeks (p = 0.006) of treatment, especially among patients using ETV. Here, our study demonstrated that heterozygous mutations in rs2296651 enhanced the antiviral response of first-line NAs and helped to explore the possibility of combining NAs and NTCP blockers for a better anti-HBV effect. |
format | Online Article Text |
id | pubmed-7943921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79439212021-03-11 The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment Wu, Lina Xu, Wenxiong Li, Xuejun Liu, Ying Wang, Lu Zhu, Shu Yang, Fangji Xie, Chan Peng, Liang Front Pharmacol Pharmacology Sodium taurocholate cotransporting polypeptide (NTCP) acts as a cellular receptor for the hepatitis B virus infection of host hepatocytes. Previously, many studies confirmed that the NTCP p.Ser267Phe variant was a protective factor against HBV-related disease progression. We therefore designed this study to investigate whether the NTCP p.Ser267Phe variant exerts an additive anti-HBV effect in chronic hepatitis B (CHB) patients on mainstream NAs treatment. After propensity score matching (PSM), a total of 136 CHB patients were included, among whom 68 were heterozygous carriers and 68 were wild-type controls. Proportions of primary nonresponse, partial virological response, virological breakthrough and hepatitis B reactivation and the HBV DNA clearance rate at each time point were compared using the chi-square test. Kaplan-Meier analysis and matched t-tests were also performed to estimate the speed of viral clearance and serum HBV DNA reduction, respectively. The proportion of primary nonresponse was significantly lower in heterozygous carriers than in wild-type controls (p < 0.001), especially in patients using entecavir (p = 0.013). Specifically, heterozygous carriers achieved HBV DNA clearance faster than wild-type controls (log-rank p = 0.0198). HBV DNA levels were reduced more in heterozygous carriers after 12 weeks (p < 0.001) and 24 weeks (p = 0.006) of treatment, especially among patients using ETV. Here, our study demonstrated that heterozygous mutations in rs2296651 enhanced the antiviral response of first-line NAs and helped to explore the possibility of combining NAs and NTCP blockers for a better anti-HBV effect. Frontiers Media S.A. 2021-02-24 /pmc/articles/PMC7943921/ /pubmed/33716744 http://dx.doi.org/10.3389/fphar.2021.616858 Text en Copyright © 2021 Wu, Xu, Li, Liu, Wang, Zhu, Yang, Xie and Peng. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wu, Lina Xu, Wenxiong Li, Xuejun Liu, Ying Wang, Lu Zhu, Shu Yang, Fangji Xie, Chan Peng, Liang The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment |
title | The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment |
title_full | The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment |
title_fullStr | The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment |
title_full_unstemmed | The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment |
title_short | The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment |
title_sort | ntcp p.ser267phe variant is associated with a faster anti-hbv effect on first-line nucleos(t)ide analog treatment |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943921/ https://www.ncbi.nlm.nih.gov/pubmed/33716744 http://dx.doi.org/10.3389/fphar.2021.616858 |
work_keys_str_mv | AT wulina thentcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT xuwenxiong thentcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT lixuejun thentcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT liuying thentcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT wanglu thentcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT zhushu thentcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT yangfangji thentcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT xiechan thentcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT pengliang thentcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT wulina ntcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT xuwenxiong ntcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT lixuejun ntcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT liuying ntcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT wanglu ntcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT zhushu ntcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT yangfangji ntcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT xiechan ntcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment AT pengliang ntcppser267phevariantisassociatedwithafasterantihbveffectonfirstlinenucleostideanalogtreatment |